Vagus nerve stimulation for the treatment of medically intractable seizures: Results of a 1-year open-extension trial

Martin Salinsky, Basim M. Uthman, Ruzica K. Ristanovic, J. F. Wernicke, W. Brent Tarver

Research output: Contribution to journalArticle

128 Citations (Scopus)

Abstract

Background: Chronic vagus nerve stimulation (VNS) continues to be evaluated as an adjunctive treatment for medically intractable seizures. A previous randomized controlled trial of 114 patients demonstrated a significant decrease in seizure frequency during 3 months of VNS at effective stimulation levels. Objective: To evaluate the efficacy of 1 year of VNS therapy for the treatment of medically refractory partial seizures and the relationship between initial and long-term response. Patients and Methods: All patients exiting the randomized controlled study of VNS for treatment of medically refractory partial seizures were offered indefinite treatment extension as part of an open-label trial. One hundred (88%) of 114 patients completed 12 months of VNS treatment at effective stimulation levels. Fourteen patients discontinued VNS treatment prior to 1 year, principally because of the treatment's lack of efficacy. These 14 patients were retained in the present analysis using an intent-to-treat approach. Antiepileptic drug use was monitored throughout the trial. Seizure frequency was analyzed in 4 sequential 3-month treatment periods. Results: Compared with pretreatment baseline, there was a significant decrease in seizure frequency during each of the 3-month treatment periods. Seizure frequency was reduced by a median of 20% during the first 3 months of VNS treatment and by 32% during stimulation months 10 through 12. Response during the first 3 months of VNS treatment was a statistically significant predictor of response at months 10 through 12. The observed reduction in seizure frequency was not explained by overall changes in antiepileptic drug use. Conclusions: The results indicate that VNS remains an effective adjunctive therapy for medically refractory partial seizures over a period of at least 1 year. Response during the first 3 months of treatment is predictive of long-term response.

Original languageEnglish (US)
Pages (from-to)1176-1180
Number of pages5
JournalArchives of Neurology
Volume53
Issue number11
StatePublished - Nov 1996

Fingerprint

Vagus Nerve Stimulation
Seizures
Therapeutics
Nerve
Stimulation
Anticonvulsants

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Salinsky, M., Uthman, B. M., Ristanovic, R. K., Wernicke, J. F., & Tarver, W. B. (1996). Vagus nerve stimulation for the treatment of medically intractable seizures: Results of a 1-year open-extension trial. Archives of Neurology, 53(11), 1176-1180.

Vagus nerve stimulation for the treatment of medically intractable seizures : Results of a 1-year open-extension trial. / Salinsky, Martin; Uthman, Basim M.; Ristanovic, Ruzica K.; Wernicke, J. F.; Tarver, W. Brent.

In: Archives of Neurology, Vol. 53, No. 11, 11.1996, p. 1176-1180.

Research output: Contribution to journalArticle

Salinsky, Martin ; Uthman, Basim M. ; Ristanovic, Ruzica K. ; Wernicke, J. F. ; Tarver, W. Brent. / Vagus nerve stimulation for the treatment of medically intractable seizures : Results of a 1-year open-extension trial. In: Archives of Neurology. 1996 ; Vol. 53, No. 11. pp. 1176-1180.
@article{dc5a82ce6258461f84ae253feab2a1b2,
title = "Vagus nerve stimulation for the treatment of medically intractable seizures: Results of a 1-year open-extension trial",
abstract = "Background: Chronic vagus nerve stimulation (VNS) continues to be evaluated as an adjunctive treatment for medically intractable seizures. A previous randomized controlled trial of 114 patients demonstrated a significant decrease in seizure frequency during 3 months of VNS at effective stimulation levels. Objective: To evaluate the efficacy of 1 year of VNS therapy for the treatment of medically refractory partial seizures and the relationship between initial and long-term response. Patients and Methods: All patients exiting the randomized controlled study of VNS for treatment of medically refractory partial seizures were offered indefinite treatment extension as part of an open-label trial. One hundred (88{\%}) of 114 patients completed 12 months of VNS treatment at effective stimulation levels. Fourteen patients discontinued VNS treatment prior to 1 year, principally because of the treatment's lack of efficacy. These 14 patients were retained in the present analysis using an intent-to-treat approach. Antiepileptic drug use was monitored throughout the trial. Seizure frequency was analyzed in 4 sequential 3-month treatment periods. Results: Compared with pretreatment baseline, there was a significant decrease in seizure frequency during each of the 3-month treatment periods. Seizure frequency was reduced by a median of 20{\%} during the first 3 months of VNS treatment and by 32{\%} during stimulation months 10 through 12. Response during the first 3 months of VNS treatment was a statistically significant predictor of response at months 10 through 12. The observed reduction in seizure frequency was not explained by overall changes in antiepileptic drug use. Conclusions: The results indicate that VNS remains an effective adjunctive therapy for medically refractory partial seizures over a period of at least 1 year. Response during the first 3 months of treatment is predictive of long-term response.",
author = "Martin Salinsky and Uthman, {Basim M.} and Ristanovic, {Ruzica K.} and Wernicke, {J. F.} and Tarver, {W. Brent}",
year = "1996",
month = "11",
language = "English (US)",
volume = "53",
pages = "1176--1180",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "11",

}

TY - JOUR

T1 - Vagus nerve stimulation for the treatment of medically intractable seizures

T2 - Results of a 1-year open-extension trial

AU - Salinsky, Martin

AU - Uthman, Basim M.

AU - Ristanovic, Ruzica K.

AU - Wernicke, J. F.

AU - Tarver, W. Brent

PY - 1996/11

Y1 - 1996/11

N2 - Background: Chronic vagus nerve stimulation (VNS) continues to be evaluated as an adjunctive treatment for medically intractable seizures. A previous randomized controlled trial of 114 patients demonstrated a significant decrease in seizure frequency during 3 months of VNS at effective stimulation levels. Objective: To evaluate the efficacy of 1 year of VNS therapy for the treatment of medically refractory partial seizures and the relationship between initial and long-term response. Patients and Methods: All patients exiting the randomized controlled study of VNS for treatment of medically refractory partial seizures were offered indefinite treatment extension as part of an open-label trial. One hundred (88%) of 114 patients completed 12 months of VNS treatment at effective stimulation levels. Fourteen patients discontinued VNS treatment prior to 1 year, principally because of the treatment's lack of efficacy. These 14 patients were retained in the present analysis using an intent-to-treat approach. Antiepileptic drug use was monitored throughout the trial. Seizure frequency was analyzed in 4 sequential 3-month treatment periods. Results: Compared with pretreatment baseline, there was a significant decrease in seizure frequency during each of the 3-month treatment periods. Seizure frequency was reduced by a median of 20% during the first 3 months of VNS treatment and by 32% during stimulation months 10 through 12. Response during the first 3 months of VNS treatment was a statistically significant predictor of response at months 10 through 12. The observed reduction in seizure frequency was not explained by overall changes in antiepileptic drug use. Conclusions: The results indicate that VNS remains an effective adjunctive therapy for medically refractory partial seizures over a period of at least 1 year. Response during the first 3 months of treatment is predictive of long-term response.

AB - Background: Chronic vagus nerve stimulation (VNS) continues to be evaluated as an adjunctive treatment for medically intractable seizures. A previous randomized controlled trial of 114 patients demonstrated a significant decrease in seizure frequency during 3 months of VNS at effective stimulation levels. Objective: To evaluate the efficacy of 1 year of VNS therapy for the treatment of medically refractory partial seizures and the relationship between initial and long-term response. Patients and Methods: All patients exiting the randomized controlled study of VNS for treatment of medically refractory partial seizures were offered indefinite treatment extension as part of an open-label trial. One hundred (88%) of 114 patients completed 12 months of VNS treatment at effective stimulation levels. Fourteen patients discontinued VNS treatment prior to 1 year, principally because of the treatment's lack of efficacy. These 14 patients were retained in the present analysis using an intent-to-treat approach. Antiepileptic drug use was monitored throughout the trial. Seizure frequency was analyzed in 4 sequential 3-month treatment periods. Results: Compared with pretreatment baseline, there was a significant decrease in seizure frequency during each of the 3-month treatment periods. Seizure frequency was reduced by a median of 20% during the first 3 months of VNS treatment and by 32% during stimulation months 10 through 12. Response during the first 3 months of VNS treatment was a statistically significant predictor of response at months 10 through 12. The observed reduction in seizure frequency was not explained by overall changes in antiepileptic drug use. Conclusions: The results indicate that VNS remains an effective adjunctive therapy for medically refractory partial seizures over a period of at least 1 year. Response during the first 3 months of treatment is predictive of long-term response.

UR - http://www.scopus.com/inward/record.url?scp=0029795080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029795080&partnerID=8YFLogxK

M3 - Article

C2 - 8912492

AN - SCOPUS:0029795080

VL - 53

SP - 1176

EP - 1180

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 11

ER -